Overview
Sermorelin is a synthetic analog comprising the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). It retains full activity at the GHRH receptor and was the first GHRH analog to receive FDA approval (1997, under the name Geref) for the treatment of idiopathic growth hormone deficiency in children. This approval was subsequently withdrawn in 2008 for commercial reasons, not safety concerns, and compounding pharmacies in the US continued prescribing it for anti-aging and GH deficiency indications. Sermorelin has an older and more established clinical record than CJC-1295 or modified GRF variants, with published data from the 1980s through 2000s including pediatric GH deficiency trials and adult anti-aging studies. Its shorter half-life (compared to CJC-1295) produces a more physiological, pulsatile GH release.
Mechanism
Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs, stimulating intracellular cAMP accumulation and GH synthesis and release. Unlike CJC-1295 (which has albumin-binding DAC technology), sermorelin has a very short half-life of approximately 10–20 minutes, producing a sharp GH pulse that mimics physiological nighttime GH release patterns more closely than long-acting analogs.
Research Areas
Side Effects (Preclinical)
- – Facial flushing
- – Injection-site redness
- – Headache
- – Nausea at higher doses
- – Water retention
Cautions
- – For research use only — compounding pharmacy prescriptions are distinct from research-grade material
- – GH axis stimulation carries shared theoretical risks with other GHRH analogs
- – Pituitary neoplasm or hypopituitarism should be excluded in clinical settings
What the research shows
Sermorelin has the longest clinical track record of any GHRH analog in this category. Its once-nightly subcutaneous dosing protocol capitalizes on the natural nocturnal GH surge, and studies have shown improvements in body composition, sleep quality, and GH axis function in GH-deficient adults.
Its short half-life, while requiring more frequent dosing than CJC-1295, is viewed favorably by researchers who prioritize physiological pulsatility over sustained elevation, as sustained high GH levels may carry different risk profiles than pulsatile release.
References
- Growth hormone-releasing hormone in growth hormone deficiency: diagnostic and therapeutic aspects — Laron Z et al. (1992)
- Growth hormone-releasing hormone as a primary therapy for adult growth hormone deficiency — Khorram O et al. (1997)